Neglected Tropical Disease Treatment Market by Type and Geography

Global Neglected Tropical Disease Treatment Market: About this market

Neglected tropical diseases are caused by pathogens such as parasites, bacteria, and virus. The neglected tropical disease treatment market considers the treatment of neglected tropical diseases using antiparasitic drugs, antibacterial drugs, and antiviral drugs. Our analysis also considers growth opportunities in Asia, North America, and ROW. In 2018, the antiparasitic drugs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of parasite-infected diseases will play a significant role in the antiparasitic drugs segment to maintain its market position. Also, our global neglected tropical disease treatment market report looks at factors such as initiatives to increase awareness and access to medicines for neglected tropical diseases, high morbidity rates, and increased funding in R&D. However, challenges associated with diagnosing neglected tropical diseases, challenges associated with drug discovery for neglected tropical diseases, and the increase in drug resistance may hamper the growth of the neglected tropical disease treatment industry over the forecast period.

Global Neglected Tropical Disease Treatment Market: Overview

Initiatives to increase awareness and access to medicines for neglected tropical diseases

The growing prevalence of neglected tropical diseases in tropical and subtropical countries has led many organizations across the world to increase awareness and to ensure easy availability of drugs for the treatment of such diseases. For instance, the Global Buruli Ulcer initiative by the World Health Organization (WHO) is aimed at improving awareness about Buruli ulcer disease. Several other organizations across the world are taking initiatives to improve the access of medicines, vaccines, and diagnostics for the treatment of neglected tropical diseases in low and middle-income countries. These developments are expected to drive the growth of the global neglected tropical disease treatment market size at a CAGR of almost 5% during the forecast period.

Development and approval of therapeutics for neglected tropical diseases

The high incidence of neglected tropical diseases such as dengue, lymphatic filariasis, trachoma, and leishmaniasis have encouraged researchers to focus on developing therapeutics for such diseases. For instance, researchers at the University Hospitals Cleveland Medical Center have developed a drug to treat patients with lymphatic filariasis. The drug is currently in Phase II of clinical trials. Many such advancements in drug development will aid in the treatment of many neglected tropical diseases and also fuel the market’s growth.

Competitive Landscape

With the presence of a few players, the global neglected tropical disease treatment market is fairly concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug manufacturers, that include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.

Also, the neglected tropical disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

Preface

Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Antiparasitic drugs - Market size and forecast 2018-2023

Antibacterial drugs - Market size and forecast 2018-2023

Antiviral drugs - Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

ROW - Market size and forecast 2018-2023

Asia - Market size and forecast 2018-2023

North America - Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE

List of Exhibits

Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Diseases caused by organisms
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antiparasitic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antiparasitic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antibacterial drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antibacterial drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antiviral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antiviral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer AG - Vendor overview
Exhibit 45: Bayer AG - Business segments
Exhibit 46: Bayer AG - Organizational developments
Exhibit 47: Bayer AG - Geographic focus
Exhibit 48: Bayer AG - Segment focus
Exhibit 49: Bayer AG - Key offerings
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: Novartis AG - Vendor overview
Exhibit 63: Novartis AG - Business segments
Exhibit 64: Novartis AG - Organizational developments
Exhibit 65: Novartis AG - Geographic focus
Exhibit 66: Novartis AG - Segment focus
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Pfizer Inc. - Vendor overview
Exhibit 69: Pfizer Inc. - Business segments
Exhibit 70: Pfizer Inc. - Organizational developments
Exhibit 71: Pfizer Inc. - Geographic focus
Exhibit 72: Pfizer Inc. - Segment focus
Exhibit 73: Pfizer Inc. - Key offerings
Exhibit 74: Validation techniques employed for market sizing
Exhibit 75: Definition of market positioning of vendors

Executive Summary

The following companies are recognised as the key players in the global neglected tropical disease treatment market: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development and approval of therapeutics for neglected tropical diseases.”

According to the report, one of the major drivers for this market is the initiatives to increase awareness and access to medicines for neglected tropical diseases.

Further, the report states that one of the major factors hindering the growth of this market is the challenges associated with diagnosing neglected tropical diseases.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.